| Metric | FY2022 | FY2021 |
|---|---|---|
| Total revenue | $0-100.0% | $120K |
| Selling, general and administrative | $40.2M+117.0% | $18.5M |
| Research and development | $32.7M+66.0% | $19.7M |
| Cost of goods sold | $1.3M | $0 |
| Impairment of acquired contract intangible asset | $3.7M-95.0% | $74.2M |
| Total operating expenses | $77.9M-30.7% | $112.3M |
| Loss from operations | -$62.7M+43.6% | -$111.2M |
| Change in fair value of convertible promissory notes | $0-100.0% | $1.6M |
| Gain upon extinguishment of debt | $0-100.0% | $196K |
| Interest income | $2.4M+18346.2% | $13K |
| Interest expense | -$230K+65.4% | -$665K |
| Total other income, net | $2.2M+92.0% | $1.1M |
| Loss before income tax expense | -$60.5M+45.0% | -$110.1M |
| Income tax expense | $0+100.0% | -$2K |
| Net loss | -$60.5M+45.0% | -$110.1M |
| Cumulative dividends on convertible preferred stock | $0+100.0% | -$647K |
| Net loss attributable to common shareholders, basic | -$60.5M+45.4% | -$110.7M |
| Net loss attributable to common shareholders, diluted | -$60.5M+45.4% | -$110.7M |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -$2.69+78.3% | -$12.41 |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -$2.69+78.3% | -$12.41 |
| Weighted average number of common shares outstanding used in computing net loss per share attributable to common stockholders, basic (in shares) | $22511237.00+152.3% | $8923369.00 |
| Weighted average number of common shares outstanding used in computing net loss per share attributable to common stockholders, diluted (in shares) | $22511237.00+152.3% | $8923369.00 |
| Product sales, net | ||
| License revenue | ||
| Grant revenue | ||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.